EUVIMEDEUVIMED entdecken
Multizentrische Studie

Evaluation of the Toxicity and Outcomes of the Combination of Midostaurin and CLAG-M in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML): A Multicenter Retrospective Analysis

Ashley Chen iD, Grace Baek iD, Kathryn Russell, Carole Shaw, Megan Othus, Jonathan Cohen, Shannon Palmer, Jack Rasmussen iD, Joseph Bubalo, Tenzin Tsomo, Tenley Schwarz, Swathi Namburi und 1 weitere

Annals of Pharmacotherapy · 2025

DOI: 10.1177/10600280241305608 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Pharmacotherapy, 2025. Verfasst von Ashley Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, UW Medicine, Fred Hutchinson Cancer Center, Seattle, WA, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Staurosporine, fms-Like Tyrosine Kinase 3, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Addition of midostaurin to standard “7+3” (cytarabine and anthracycline) significantly prolongs overall and event-free survival. At University of Washington/Fred Hutchinson Cancer Center (UW/FHCC), the standard regimen for newly diagnosed (ND) and relapsed/refractory (R/R) AML is cladribine, high-dose cytarabine, GCSF, and mitoxantrone (CLAG-M); midostaurin is added if FLT3-mutated. There is limited data on the use of FLT3-inhibitors with high-dose cytarabine regimens in AML.

Objective

This study aimed to evaluate the safety and efficacy of the combination of midostaurin with CLAG-M versus midostaurin plus 7+3 in FLT3-mutated AML patients.

Methods

This is a retrospective, multicenter review including FLT3-mutated AML patients undergoing (re)induction chemotherapy with either CLAG-M or 7+3 at UW/FHCC, Oregon Health & Science University, and Swedish Cancer Institute. The primary outcome was incidence of adverse events. Secondary outcomes included disease response per ELN2017 criteria and 28-day mortality. Excluded were patients on clinical trials or who started midostaurin 30 days after chemotherapy.

Results

Eighty patients treated from September 2016 to December 2023 were included; 36 patients received CLAG-M, and 44 patients 7+3. Baseline characteristics were similar across all institutions. Adverse event rates were similar between the 2 cohorts, except diarrhea and bleeding which were more common in the 7+3 cohort. The rate of complete remission (CR) plus CR with incomplete blood count recovery did not significantly differ between the 2 cohorts: CLAG-M, 86% versus 7+3, 70% ( P = 0.11). Conclusion & relevance: The toxicity profile of CLAG-M combined with midostaurin is comparable with the combination of 7+3 with midostaurin, and induces high remissions rates in adults with FLT3-mutated AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteStaurosporinefms-Like Tyrosine Kinase 3Antineoplastic Combined Chemotherapy ProtocolsHumansRetrospective StudiesMaleFemaleMiddle AgedAgedAdultCytarabineMitoxantroneMutationCladribineTreatment OutcomeGranulocyte Colony-Stimulating FactorYoung Adult

Stichwörter der Autor:innen

7+3AMLCLAG-MFLT3

Substanzen

midostaurinStaurosporinefms-Like Tyrosine Kinase 3FLT3 protein, humanCytarabineMitoxantroneCladribineGranulocyte Colony-Stimulating Factor

Autor:innen und Institutionen

  • Department of Pharmacy, UW Medicine, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Department of Hematologic Malignancies, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Department of Statistics, UW Medicine, Seattle, WA, USA.
  • Department of Pharmacy, Oregon Health & Science University, Portland, OR, USA.
  • Swedish Cancer Institute, Seattle, WA, USA.

ORCID-Profile: Ashley Chen, Grace Baek, Jack Rasmussen

Zitieren

APA

Chen, A., Baek, G., Russell, K., Shaw, C., Othus, M., Cohen, J., Palmer, S., Rasmussen, J., Bubalo, J., Tsomo, T., Schwarz, T., Namburi, S., & Halpern, A. (2025). Evaluation of the Toxicity and Outcomes of the Combination of Midostaurin and CLAG-M in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML): A Multicenter Retrospective Analysis. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280241305608

Vancouver

Chen A, Baek G, Russell K, Shaw C, Othus M, Cohen J, et al. Evaluation of the Toxicity and Outcomes of the Combination of Midostaurin and CLAG-M in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML): A Multicenter Retrospective Analysis. Annals of Pharmacotherapy. 2025. doi:10.1177/10600280241305608

BibTeX
@article{Chen2025,
  author = {Chen, Ashley and Baek, Grace and Russell, Kathryn and Shaw, Carole and Othus, Megan and Cohen, Jonathan and Palmer, Shannon and Rasmussen, Jack and Bubalo, Joseph and Tsomo, Tenzin and Schwarz, Tenley and Namburi, Swathi and Halpern, Anna},
  title = {Evaluation of the Toxicity and Outcomes of the Combination of Midostaurin and CLAG-M in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML): A Multicenter Retrospective Analysis},
  journal = {Annals of Pharmacotherapy},
  year = {2025},
  doi = {10.1177/10600280241305608}
}
Kostenlos starten →